Skip to content

Return on assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
10.7%-1.3pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
15.6%+7.0pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
27.4%+4.4pp
AbbVie logo
AbbVieABBV
2.7%-0.3pp
LBR
LB Pharmaceuticals Inc Common StockLBRX
-14.5%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

Based on trailing twelve months.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's return on assets?
MapLight Therapeutics, Inc. (MPLT) reported return on assets of -52.3% in Q4 2025.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.